Using gene and protein expression analysis Holmes, Thong & coll, first report that Aiolos expression is relatively stable along NK cell development. Flow cytometric analysis of the different NK cell development stages then reveal that despite a relatively unimpaired NK cell numbers, Aiolos deficiency leads to a cell-instrinsic severe block in the transition from immature to mature NK cells. Interestingly, despite this stringent phenotype, follow-up ex vivo analyses of NK cells functions from those mice reveal only mild defects in their abilities to secrete cytokines or produce cytotoxic molecules. In vivo, the authors report that MCMV virus clearance is slightly delayed, whereas clearance of NK-sensitive tumors is significantly enhanced. Mechanistically, the authors report that Aiolos does not seem to be regulated or regulate the expression of the transcription factors T-bet, Eomes and Blimp-1, that are critically involved in the transition from immature to mature stages. Based on these results, the authors conclude that while Aiolos by itself does not play a role in the early steps of NK cell differentiation, it critically acts in peripheral NK cell finally through a novel regulatory circuit, i.e. independent of the others known regulators of this process.
Overall, the general conclusion of this study is well supported by the presented data and is definitely of interest, although it could benefit from answering the following points:
1. Mechanistic insights regarding this differentiation block: spontaneous death of immature cells ? lack of survival of mature cells ? impaired proliferation ?
2. The authors describe the appearance of an 'aberrant' CD27+ KLRG1+ population in Aiolos deficient mice, with low expression of CD11b and Ly49C but high expression of cKit and CD51. Considering that KLRG1 expression is upregulated on proliferating NK cells, the use of this marker in phenotypic analyses of NK cell development might blur the actual description of the different NK cells differentiation stages. Indeed, another possibility is that this KLRG1+ phenotype just results from an NK-penia driven homeostatic proliferation of normal immature NK cells (CD122+ NK1.1+ Dx5+ CD27+ ckit+ CD11b-/lo NKG2+ Ly49D/H+ Ly49C-).
3. As the authors point out a few times, although not really precisely described to date, NK cell subpopulations are known to have distinct functional patterns in terms of cytokine secretion, cytotoxic potential and trafficking. Considering the very significant different repartition of the various cell subpopulations between Aiolos knock out mice and wild type mice, and the fact that all functional assays are done on total NK cells, it is difficult to interpret the functional differences. So, in order to carefully study the potential role of Aiolos in NK cell functions, experiments using sorted cell populations would have to be performed. As an example, in Fig 4 in vitro experiments reveal a modest, if any, increase in IL-15 driven proliferation, and argue that this can stem from the known enhanced proliferative capacity of CD27+ cells. Moreover, in Fig3D, the author show that CD122 seems to be enhanced on Aiolos KO spleen cells compared to WT cells thus suggesting that IL-15 sensitivity can be different between the 2 cell populations. It would be interesting to know if CD122 expression is really enhanced as a consequence of Aiolos deficiency, or if a normal differential expression between immature and mature subpopulations might explains this results considering the absence of mature cells in Aiolos KO mice. Figure 4 legend's indicates that the cytotoxic activity is tested against RMA-S-Rae1 cells (MHC-I deficient AND NKG2D triggering) and not RMA-S cells. As opposed to the author's statement in the manuscript, NK cell cytotoxic activity in this assay therefore does not only results from a lack of MHC-I expression.
4.
5. Throughout the manuscript, the authors should present the stages of NK cell maturation by using the most usual way (CD27 and CD11b histogram plot) rather than CD27 and KLRG1.
Referee #2:
The authors investigate the role of the transcription factor Aiolos for NK cell development and function. Expression of Aiolos was induced at the pre-pro NK cell stage and Aiolos remained expressed during differentiation down the NK lineage. Mice genetically deficient for Ikzf3, the gene encoding Aiolos, had normal numbers of NK cells in spleen and bone marrow. Ikzf3-deficient NK cells remained CD27+ and did not mature into the CD27-KLRG1+ state. Ikzf3-deficient NK cells produced less IFN-g and had lower levels of GzmB in comparison to wildtype NK. However, Ikzfdeficient NK cells were as effective as their wildtype controls in killing target cells when stimlated with IL-15 alone or in combinaton with IL-21. Aiolos expression was independent of T-bet or Blimp1 and T-bet, Eomes and Blimp1 expression was normal in Ikzf3-deficient mice. Mice genetically lacking Ikzf3 were more susceptible to MCMV and showed reduced rejection of RMA-S and B16 tumors.
General comments
This is an interesting manuscript investigating the role of the transcription factor Aiolos for differentiation and function of NK cells which has been largely ignored in the past. While the experiments seem carefully designed, the data does not provide much mnechanistic insights into how Aiolos controls differentiation and function of NK cells. A revised manuscript addressing the specific points below may be suitable for publication in EMBO J. 2. There is a tendency to higher absolute NK cell numbers in the spleen of Ikzf3-deficient mice ( Figure 3E ) which is in contrast to lower proliferation in vitro in response to IL-15 ( Figure 5A 4. The increased susceptibilty to MCMV has to be further investigated. NK cell function (IFN-g production, NK population expansion, cytotoxicity, migration/recruitment) needs to be analyzed. The reduced virus control in salivary glands is puzzling because virus control in salivary glands is believed to be CD4 T cell-dependent. Could Ikzf3 deficiency in CD4 T cells contribute to the observed phenotype?
Referee #3:
To the Authors:
The authors describe how the transcription factor Aiolos regulates maturation and function of peripheral NK cells. The role of Aiolos in NK cell development and maturation has not been previously studied, thus the data are novel. However, many of the findings appear contradictory and confusing. The lack of consistency throughout the manuscript is concerning.
There are at least 3 pieces of data that are not consistent. In particular data in figure 4 suggests differences in cytokine production and cytotoxicity between WT and KO NK cells, whereas figure 5 then shows normal killing and cytokine production. Furthermore, it is confusing why Aiolosdeficient mice are more susceptible to virus but more resistant to tumors. The explanation in the discussion is not convincing because it is known that cytotoxicity via activating Ly49H receptor and perforin/granzyme release that mediates resistance against MCMV. Take away the Ly49H receptor or effector molecules, and mice are extremely susceptible to MCMV infection. Lastly, Aiolos-/-NK cells mediate the same degree of cytotoxicity against missing-self tumors in vitro in figure 5, but kill missing-self tumors better in vivo in figure 7. Why is this so? The manuscript contains many findings that lack consistency.
Perhaps the discrepancy between virus and tumor can be explained by differences in adaptive immunity between WT and Aiolos-/-mice. Are T and B cell responses defective in Aiolos-/-mice during virus and tumor challenge? In the viral challenge model, the differences in viral titer between the two groups of mice at day 10 and 18 can be explained by differences in CD8+ T cell responses. Have these been measured? The late influences (beyond the first couple of days) of Aiolosdeficiency can also be ruled out by crossing mice to a RAG-deficient background.
The clonal-like expansion of a specialized subset of NK cells expressing the Ly49H receptor is responsible for protection against virus. Is this Ly49H NK cell expansion defective in Aiolos-/-mice? This could be another explanation for the higher viral titers.
It is surprising that decreased overall expression of IFNy and granzyme B in Aiolos-/-mice leads to increased tumor control of RMA/s and B16, especially due to the fact that the in vitro killing of RMA/s RAE1b is similar between WT and KO. Could this be due to enhanced infiltration of immature NK cells in these tumors? Or loss of inhibition by downregulation of KLRG1? Characterization of the tumor-infiltrating NK cells would greatly strengthen this paper.
Minor:
The discussion section uses CD27 and CD11b to describe the maturation stages of NK cells. However, throughout the manuscript, the authors make no use of these markers together to examine NK cell maturation. As this group first described use of these markers in combination, it would be beneficial to show some of this staining. It is unclear why this group has chosen to substitute KLRG1 for CD11b in all of their phenotyping data. Why was this done? Are these 2 markers interchangeable? CD27 should be shown versus CD11b in the panels of these figures to reach consensus with the majority of published literature on NK cell maturation.
In the final paragraph of their discussion, the authors talk about how less mature NK cells (CD27hi) have a higher proliferative potential during IL-15 in vitro stimulation or during lymphopenia, and how this might explain the greater protection against tumor challenge. This does not make sense. Why would the tumor microenvironment mimic IL-15 in vitro or lymphopenia? Presumably more mature NK cells possessing higher cytotoxicity would favor tumor clearance. Is there evidence that CD27+KLRG1-NK cells are more protective than CD27-KLRG1+ NK cells against tumors in vitro or in vivo?
Figures 1 and 2 should be combined. In figure 1 , although the authors state that the cell sorting strategy will be explained in a supposed future publication, it would be beneficial to include the representative gating strategy in order to fully understand and interpret the RNA seq data.
The numbering of Figure 3 doesn't make sequential sense. Figure 3E should be relabeled 3B. 
Referee #1:
In this paper by the group of Stephen Nutt, a well-known investigator in the field of immunopoiesis, the authors analyze the role of Aiolos in NK cell development. … Although Aiolos deficient mice have been engineered more than 15 years ago, the present study is the first to analyze their NK cell compartment and thus is off great interest. …….Overall, the general conclusion of this study is well supported by the presented data and is definitely of interest, although it could benefit from answering the following points: (Figure 2A-B 3. As the authors point out a few times, although not really precisely described to date, NK cell subpopulations are known to have distinct functional patterns in terms of cytokine secretion, cytotoxic potential and trafficking. Considering the very significant different repartition of the various cell subpopulations between Aiolos knock out mice and wild type mice, and the fact that all functional assays are done on total NK cells, it is difficult to interpret the functional differences. So, in order to carefully study the potential role of Aiolos in NK cell functions, experiments using sorted cell populations would have to be performed. As an example, in Fig 4 in Figure 1 4. Figure 4 legend's indicates that the cytotoxic activity is tested against RMA-S-Rae1 cells (MHC-I deficient AND NKG2D triggering) and not RMA-S cells. As opposed to the author's statement in the manuscript, NK cell cytotoxic activity in this assay therefore does not only results from a lack of MHC-I expression.
RESPONSE:
We thank the reviewer for pointing out this oversight. We have now modified the text accordingly.
5. Throughout the manuscript, the authors should present the stages of NK cell maturation by using the most usual way (CD27 and CD11b histogram plot) rather than CD27 and KLRG1. Figure 2C) , as well as determined Aiolos protein expression using these markers ( Figure 1D) 
RESPONSE: We agree with the reviewer and have added a series of panels showing CD27 versus CD11b in +/+ and Ikzf3 -/-NK cells from bone marrow and spleen (New

Referee #2:
….General comments This is an interesting manuscript investigating the role of the transcription factor Aiolos for differentiation and function of NK cells, which has been largely ignored in the past. While the experiments seem carefully designed, the data does not provide much mechanistic insights into how Aiolos controls differentiation and function of NK cells. A revised manuscript addressing the specific points below may be suitable for publication in EMBO J. Figure 3 .
Specific Comments
This analysis revealed that Aiolos does not exert its function through the regulation of any known transcriptional regulators of the NK cell lineage (Figure 3F) and that the other members of the Ikaros family were not upregulated in compensation for Aiolos loss. (Figure 3F). Moreover, despite the similarities in the knockout phenotypes Aiolos does not appear to be regulated by either T-bet, Blimp1 or both.
2. There is a tendency to higher absolute NK cell numbers in the spleen of Ikzf3-deficient mice ( Figure 3E ) which is in contrast to lower proliferation in vitro in response to IL-15 ( Figure 5A ,B). How can this be explained? Figure 5C ,D) but tumor rejection in vivo was significantly impaired (Figure 7B-E) . What is the mechanism of tumor rejection if not cytotoxicity? Figure 2G that the Ikzf3 -/-NK cells hyper-respond to and in Figure 6F that (Hayakawa and Smyth J Immunol 176,1517 -1524 (2006 and Huntington et al J Immunol 178,4764-4770 (2007) ), we propose that the common g chain receptor hyperresponsiveness and block at the CD27 + stage underpins the improved tumor control.
RESPONSE: The original Figure 5A, B (now removed from the manuscript) actually showed modestly increased proliferation in the absence of Aiolos and thus agreed with the higher absolute NK cell numbers in these mice. We have replaced that data with the more informative CFSE/CTV experiments (Figure 2E-F) that also show increased IL-15 responsiveness.
Ikzf3-deficient NK cells did not show reduced cytotoxicty (
RESPONSE: The reviewer has misinterpreted the in vivo data, which shows increased tumor control in Aiolos-deficient mice. Cytotoxicity in NK cells depends not only on the presence of the Perforin/Granzyme containing granules and death ligands, which are present in the Aiolos-deficient cells, but also on the activity of various activating or inhibitory pathways, as well as the frequency and location of the NK cells. We show in new
4. The increased susceptibility to MCMV has to be further investigated. NK cell function (IFN-g production, NK population expansion, cytotoxicity, migration/recruitment) needs to be analyzed. The reduced virus control in salivary glands is puzzling because virus control in salivary glands is believed to be CD4 T cell-dependent. Could Ikzf3 deficiency in CD4 T cells contribute to the observed phenotype? (Sumaria et al. Immunol Cell Biol 87, 559-566 (2009) 
RESPONSE: The reviewer raises 2 issues: (1) is there some impact of Aiolos-deficiency on adaptive immune responses and (2) is there any measurable difference in NK cell function.
1) Our data don't support any defect in the adaptive immune response being involved in the early response to MCMV. In C57/Bl6 mice T cells do not participate in the early control of acute infection
T cells and no difference in MCMV-specific (M45 tetramer binding CD8 + T cells) in the absence of Aiolos. The increase in T cell number in the spleen at day 0 is due to the mild splenomegaly that has been previously reported for these mice and reflected in the mildly increased splenic NK cell numbers (Figure 2B). This data is now provided as a Supplementary Figure 1 and discussed on page 13 of the text. The increase in viral titer in the salivary gland could be a result of more virus being present early during infection -we have observed this phenotype before in IFNg-deficient mice at day 10 post-infection and attributed to a combination of differences in viral dissemination and local effector mechanisms (latter probably CD4
+ T cell mediated, Sumaria et al. Immunol Cell Biol 87, 559-566 (2009)) . (Figure 7A) , where virus control in C57/Bl6 mice is completely dependent on perforin-dependent NK cell mediated activity (Sumaria et al Immunol Cell Biol 87, 559-566 (2009) Figure 1 and  data not shown) . We have discussed these points on page 13 of the text.
2) The results also suggest that NK cytotoxic function is largely intact, since there is no difference in viral replication in the spleen
Referee #3:
The authors describe how the transcription factor Aiolos regulates maturation and function of peripheral NK cells. The role of Aiolos in NK cell development and maturation has not been previously studied, thus the data are novel. However, many of the findings appear contradictory and confusing. The lack of consistency throughout the manuscript is concerning. There are at least 3 pieces of data that are not consistent. In particular data in Figure 4 suggests differences in cytokine production and cytotoxicity between WT and KO NK cells, whereas Figure 5 then shows normal killing and cytokine production. Furthermore, it is confusing why Aiolos-deficient mice are more susceptible to virus but more resistant to tumors. The explanation in the discussion is not convincing because it is known that cytotoxicity via activating Ly49H receptor and perforin/granzyme release that mediates resistance against MCMV. Take away the Ly49H receptor or effector molecules, and mice are extremely susceptible to MCMV infection. Lastly, Aiolos -/-NK cells mediate the same degree of cytotoxicity against missing-self tumors in vitro in Figure 5 , but kill missing-self tumors better in vivo in figure 7. Why is this so? The manuscript contains many findings that lack consistency. Figure 6F, page 14) . Thus we propose that the common g chain receptor hyperresponsiveness and block at the CD27 + stage in the absence of Aiolos underpins the improved tumor control.
RESPONSE: As outlined in our response to reviewer 2, we do not propose that Aiolos is regulating
Specifically
1. "data in figure 4 suggests differences in cytokine production and cytotoxicity between WT and KO NK cells, whereas figure 5 then shows normal killing and cytokine production". (Smyth et al J Immunol 171,515-518 (2003) . Thus these are distinct assays that measure different NK cell capabilities. 2. "confusing why Aiolos-deficient mice are more susceptible to virus but more resistant to tumors" While both these pathways use Perforin/Gzm mediated killing as the effector mechanism (MCMV control also requires IFNg (Sumaria et al. Immunol Cell Biol 87, 559-566 (2009) or subset specific functions that we discuss on page 18.
The data in Figure 4 compares the expression of two effector molecules IFNg and GzmB directly ex vivo, with those cultured for 7 days in cytokines (Figure 5). While reduced GzmB is a surrogate marker for cytotoxic potential, it is known that loss of GzmB alone does not significantly impact of these in vitro killing assays or tumor control
"Aiolos
-/-NK cells mediate the same degree of cytotoxicity against missing-self tumors in vitro in figure 5, but kill missing-self tumors better in vivo in figure 7. Why is this so?".
As discussed in point #2, we don't claim any function for Aiolos in directly controlling the killing mechanism and instead propose that the blocked differentiation at a stage known to have more killing activity in vitro and increased cell responsiveness results in better tumor control in vivo.
Perhaps the discrepancy between virus and tumor can be explained by differences in adaptive immunity between WT and Aiolos -/-mice. Are T and B cell responses defective in Aiolos -/-mice during virus and tumor challenge? In the viral challenge model, the differences in viral titer between the two groups of mice at day 10 and 18 can be explained by differences in CD8 + T cell responses. Have these been measured? The late influences (beyond the first couple of days) of Aiolosdeficiency can also be ruled out by crossing mice to a RAG-deficient background. Figure 1) . This agrees with a publication by some of us (Sumaria et al. Immunol Cell Biol 87, 559-566 (2009) Smyth et al J Immunol 165,2665 -2670 (2000 and Brady et al J Immunol 172,2048 -2058 (2004 
RESPONSE. As discussed in detail in
Minor:
The discussion section uses CD27 and CD11b to describe the maturation stages of NK cells. However, throughout the manuscript, the authors make no use of these markers together to examine NK cell maturation. As this group first described use of these markers in combination, it would be beneficial to show some of this staining. It is unclear why this group has chosen to substitute KLRG1 for CD11b in all of their phenotyping data. Why was this done? Are these 2 markers interchangeable? CD27 should be shown versus CD11b in the panels of these figures to reach consensus with the majority of published literature on NK cell maturation. Figure 2C) , as well as determined Aiolos protein expression using these markers ( Figure 1D (Hayakawa and Smyth J Immunol 176,1517 -1524 (2006 ) and have higher proliferative capacity (Hayakawa and Smyth J Immunol 176,1517 -1524 (2006 and Huntington et al J Immunol 178,4764-4770 (2007) (Kallies et al Blood 117,1869 -1879 (2011 Figures 1 and 2 should be combined. In figure 1 , although the authors state that the cell sorting strategy will be explained in a supposed future publication, it would be beneficial to include the representative gating strategy in order to fully understand and interpret the RNA seq data. Figures 1 and 2 , into a single Figure 1 . The gating strategies of the NK cell populations and the generation of the RNAseq data used in Figure 1 in are now published in Seillet J. Immunol 92:2667 -2676 (2014 (for NKP, iNK, mNK) and Carotta Blood 117:5449-5452 (2011) 
RESPONSE: We have combined
(for pre-pro-NK). These have been fully referenced in the Methods
The numbering of Figure 3 doesn't make sequential sense. Figure 3E should be relabeled 3B. Figure 3) as the reviewer suggests.
RESPONSE: We have ordered Figure 2 (formerly
2nd Editorial Decision 27 August 2014
Thank you for submitting your revised manuscript to The EMBO Journal. Your manuscript has now been re-reviewed by the three referees.
As you can see below, the referees appreciate the introduced changes and support publication in The EMBO Journal. I am therefore very pleased to accept the manuscript for publication here. There are just a few text edits to attend to before formal acceptance here. I have provided the link below so that you can upload the revised version.
REFEREE REPORTS
Referee #1:
The revised version is great. I recommend publication in the Embo J.
